A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
By S. Sim, C. Risinger, M. Dahl, E. Aklillu, M. Christensen, L. Bertilsson, Magnus Ingelman-Sundberg. Clinical pharmacology and therapy, 2006
778 citations recorded by the source corpus.
Subfields: Anesthesiology and Pain Medicine, Oncology, Pharmacology
View Paper: https://www.semanticscholar.org/paper/cbd7122f61c5da10be60933505a55991eb44238f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pharmacology
Citations in the corpus
- Polymorphism of human cytochrome P450 enzymes and its clinical impact (2009, background): “As such, the reduced warfarin dosage requirements displayed in Chinese and Malay populations strongly suggests that other factors are involved besides CYP2C9 polymorphism.”
- Tricyclic antidepressant pharmacology and therapeutic drug interactions updated (2007, background): “Indeed, it has only recently been discovered that 18% of Swedes have an ultrarapid CYP450 2C19 isoform (Sim et al., 2006b), which is likely to cause therapeutic failures with the usual doses of CYP2C19 substrates, such as proton pump inhibitors and antidepres- sants.”
- Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. (2007, methodology): “4A; Sim et al., 2006).”
- Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. (2013, background): “A further clinically relevant variant is the promoter variant –806C>T (*17) which appears to increase expression and activity toward mephenytoin and omeprazole by a still unclear mechanism (Sim et al., 2006).”
- Pharmacokinetics and drug metabolism in the elderly (2009, background): “In addition, the recently discovered new variant of CYP2C19*17 (coding for UMs) has to be included in the genotyping (Sim et al., 2006).”
- Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (2017, background): “The CYP2C19*17 allele, defined by a variant in the gene promoter region, causes enhanced gene transcription resulting in greater metabolic capacity (6) and is therefore classified as an increased function allele.”